Myriad Genetics, Salt Lake City, says that a comprehensive economic analysis of its EndoPredict test shows that the test is more than twice as cost-effective as the Oncotype Dx test from Genomic Health, Redwood City, Calif, for predicting a patient’s recurrence of breast cancer. The study’s authors analyzed the cost-benefit of various breast cancer arrays compared with the EndoPredict test.
“Payers would benefit from understanding the financial implications of using gene expression tests to determine recurrence risk in women with early-stage breast cancer,” says Malek B. Hannouf, PhD, a research associate at the London Health Sciences Center, Ontario, Canada, and lead investigator for the study. “Our study provides firm evidence validating the economic value of incorporating EndoPredict into patient care.”
The EndoPredict breast cancer recurrence test from Myriad Genetics.
The study examined the cost-effectiveness of incorporating gene expression testing into standard practice using data from the Anastrozole or Tamoxifen Alone or Combined (ATAC) clinical trial and cost data from the London Regional Cancer Program and other Canadian sources. The analysis evaluated three genetic tests compared with the clinicopathological features traditionally used to guide adjuvant treatment decisions. The primary endpoint was quality-adjusted life years (QALYs), which is a measure of the value of health outcomes. Compared with a strategy of using clinicopathological predictors alone, the results showed that EndoPredict was the single most cost-effective genetic test and was more than twice as cost-effective as market-leading Oncotype Dx. The study determined that EndoPredict has a cost per QALY of $36,274, and Oncotype Dx has a cost per QALY $74,911.
“These results advance our understanding of precision medicine for women with breast cancer and confirm that EndoPredict is the most cost-effective genetic test,” says Ralf Kronenwett, MD, PhD, director of international medical affairs at Myriad Genetics. “The findings build on prior studies that demonstrated the clinical utility of EndoPredict for predicting which women will benefit from adjunctive chemotherapy at diagnosis and who is unlikely to benefit from extended endocrine therapy 5 years after diagnosis.”
EndoPredict is a second-generation, multigene prognostic test that aids personalized treatment planning for patients with early-stage breast cancer. EndoPredict has been validated in approximately 4,000 patients with node-negative and node-positive disease and has been used clinically in more than 25,000 patients. In contrast to first-generation multigene prognostic tests, EndoPredict is validated to accurately predict both early (0–5 years) and late (5–15 years) distant recurrence. It can also predict the benefit from adjuvant chemotherapy and determine which patients can safely forgo extended endocrine therapy beyond 5 years.
For more information visit Myriad Genetics.
